Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, Pierfranco Conté, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy

New England Journal of Medicine, 2016

The University of Texas MD Anderson Cancer Center, Tel Aviv University, Rabin Medical Center, Sarah Cannon Research Institute, National Cancer Centre Singapore, The Netherlands Cancer Institute, Sheba Medical Center, Institut de Cancérologie de l'Ouest, Duke Medical Center, Université Paris-Sud, Institut Gustave Roussy, Dana-Farber Cancer Institute, Universität Ulm, University of Padua, Istituto Oncologico Veneto, Breast Cancer Research Foundation, Vanderbilt-Ingram Cancer Center, Edinburgh Cancer Research, Masaryk Memorial Cancer Institute, Florida Cancer Specialists & Research Institute, Sarah Cannon, Centre Hospitalier Universitaire de Besançon, Curtin University, Vejle Sygehus, Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser, University of Tübingen, Hospital Clínico Universitario Virgen de la Victoria, Oslo University Hospital, Virginia Cancer Specialists, Tennessee Oncology, Centre Léon Bérard, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Northwest Medical Specialties, Novartis (Switzerland), Texas Oncology, The US Oncology Network

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1967

Citations

View on Google Scholar

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back